Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Armen Yuri Gasparyan, Lilit Ayvazyan, Dimitri P. Mikhailidis and George D. Kitas
Affiliation: Dudley Group of Hospitals NHS Trust (Teaching Trust of University of Birmingham, UK), Russells Hall Hospital, North Block, Clinical Research Unit, Dudley, West Midlands DY1 2HQ, United Kingdom.
Keywords: Platelets, arterial thrombosis, venous thromboembolism, rheumatic disease, mean platelet volume, beta-cryptoxanthin, spondylarthritides, primary Sjogren's syndrome affects, alpha-carotene, tein/zeaxanthin, lycopene, tocopherol, methotrexate, synovial cell proliferation, fibrosis, pannus, prostanoids, tumor necrosis factor al-pha, monozygotic, dizygotic, MAPKs, phosphoinositide-3-kinase, systolic BP, eicosapentaenoic acid, docosa-hexaenoic acid, oleuropein, hy-droxytyrosol, tyrosol, Evening Primrose oil, dihomo-linolenic acid, dihomo-linolenic, Blackcurrant seed oil (BCSO), gammalinolenic, alphalinolenic acid, ATRA, collagen-induced arthritis (CIA), Megaloblastic anemia, glutathione peroxidase, toll-like receptors, apigenin, quercetin, genistein, epigallocatechin gallate, kappaB, Glucosamine sulfate, chondroitin sulfate, inflammation, prognosis, juvenile arthritis affects, systemic lupus erythematosus affects, luteolin, anthocyanidin resulted
Platelet activation is a link in the pathophysiology of diseases prone to thrombosis and inflammation. Numerous platelet markers, including mean platelet volume (MPV), have been investigated in connection with both thrombosis and inflammation. This review considers MPV as a prognostic and therapeutic marker as well as the factors influencing its measurement. Established cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, and diabetes, can influence MPV, depending on confounding factors. Low-grade inflammation is one such factor. Evidence, particularly derived from prospective studies and a meta-analysis, suggest a correlation between an increase in MPV and the risk of thrombosis. High MPV associates with a variety of established risk factors, cardio- and cerebrovascular disorders, and low-grade inflammatory conditions prone to arterial and venous thromboses. High-grade inflammatory diseases, such as active rheumatoid arthritis or attacks of familial Mediterranean fever, present with low levels of MPV, which reverse in the course of antiinflammatory therapy. Lifestyle modification, antihypertensive, lipid-lowering and diet therapies can also affect MPV values, but these effects need to be investigated in large prospective studies with thrombotic endpoints.
Rights & PermissionsPrintExport